SES AUA 2026
SES AUA 2026
SES AUA 2026: The State of the Urology Workforce
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured the Gee-Dineen lecture series and a presentation by Dr. Andrew Harris discussing the state of the Urology workforce. Dr. Harris started his presentation by comparing the economics of Urology to the Rolex company: driven by supply, demand, and controlled distribution. Based on data from the 2024 AUA Annual Census, it is notable that Urology has an aging workforce. The median age of practicing urologists is 54 years, with 65 years and older being the largest age group (26.3%) of urologists:
SES AUA 2026: Differences in Restaging TURBT Pathology Outcomes Based on Index TURBT Performed by an SUO Fellowship Trained or Non-SUO Trained Urologist
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Joon Kyung Kim discussing differences in restaging TURBT pathology outcomes based on index TURBT performed by an SUO fellowship trained or non-SUO trained urologist. TURBT has both diagnostic and therapeutic implications. For individuals diagnosed with T1 non muscle invasive bladder cancer, guidelines recommend restaging TURBT, given that up to 50% of individuals may have residual tumor and 20% may be understaged on repeat resection. Patients without residual T1 disease on restaging TURBT have decreased risk of recurrence and progression, and restaging TURBT can also reduce the risk of recurrence and progression compared to not performing a restaging TURBT at all.
SES AUA 2026: Bladder Cancer Burden from Smoking: Mortality and Disability-Adjusted Life Years in Relation to United States Tobacco Taxation
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a health services research session and presentation by Ryan Wong discussing mortality and disability adjusted life years in relation to United States tobacco taxation.
SES AUA 2026: Novel FDA Drug Repurposing Strategies for High-Mortality Urologic Cancers: A TCGA-Based Molecular Analysis
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured an artificial intelligence session and presentation by Dr. Garrett Brinkley discussing a TCGA-based molecular analysis assessing novel FDA drug repurposing strategies for high-mortality urologic cancers. High-mortality urologic cancers represent a critical unmet medical need, with 5-year survival rates below 10% for aggressive variants, including distant bladder cancer (6.2% survival), neuroendocrine prostate cancer (7.2%), small cell bladder cancer (8.1%), and sarcomatoid renal cell carcinoma (9.4%):
SES AUA 2026: Patient Perspectives on Pre-Treatment Counseling for Prostate Cancer: A Qualitative Analysis on Patient Communication
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a health services research session and presentation by Dr. Evalyn George discussing the patient understanding of quality of life outcomes in prostate cancer treatments. Prostate cancer is a variable disease with innumerable treatment options, each carrying unique side-effect profiles. This makes patient counseling a complicated task, necessitating a personalized approach to an individual’s goals of care and acceptable side effects.
SES AUA 2026: Application of Machine Learning Models for Predicting Postoperative Ileus after Radical Cystectomy
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured an artificial intelligence session and presentation by Dr. Mohamed Javid Raja Iyub discussing the application of machine learning models for predicting postoperative ileus after radical cystectomy. Postoperative ileus is a common complication after radical cystectomy that leads to delayed recovery and extended hospital stay. The objective of this study, presented at the SESAUA 2026 annual meeting, was to use machine learning to develop models that can predict patients with a high risk of developing postoperative ileus after radical cystectomy.
SES AUA 2026: Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE Study
- Details
(UroToday.com) The 2026 Southeastern Section of the AUA Annual Meeting featured a presentation by Dr. Zachary Klaassen of a post hoc analysis from the phase 3 ARANOTE trial evaluating darolutamide plus androgen-deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with outcomes stratified by disease volume.
SES AUA 2026: Patient Time Toxicity from Management Options for NMIBC
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Veerain Gupta discussing patient time toxicity from management options for non-muscle invasive bladder cancer. Bladder cancer is the most expensive malignancy in the US on a per-patient basis, and these costs tend to be higher for patients with non-muscle invasive bladder cancer.
SES AUA 2026: Response to Treatment with UGN-102 in Patients with Early or Late Recurrent Low-Grade Intermediate Risk NMIBC
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. William Huang discussing the response to treatment with UGN-102 in patients with early or late recurrent low-grade intermediate risk non-muscle invasive bladder cancer. Low-grade intermediate risk non-muscle invasive bladder cancer is a highly persistent and recurrent disease, where patients typically undergo treatment with repeated TURBTs under general anesthesia.
SES AUA 2026: Implementation of Patient Reported Outcomes as a NMIBC Clinical Trial Endpoint
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Spencer Bell discussing the implementation of patient-reported outcomes as a non-muscle invasive bladder cancer clinical trial endpoint.
SES AUA 2026: Assessing the Role of Girentuximab PET/CT in Clinical Decision-Making: Results from a National Survey of Urologic Oncologists
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a kidney cancer session and presentation by Dr. Gianpaolo Carpinito discussing results from a national survey of urologic oncologists assessing the role of girentuximab PET/CT in clinical decision making. Girentuximab is a chimeric antibody targeting CAIX, which is an important target given that >94% of clear cell renal cell carcinoma (RCC) are CAIX-positive. Based on data from the ZIRCON trial,1 the girentuximab PET/CT can accurately identify localized and advanced clear cell RCC by targeting CAIX and is likely to become widely available.
SES AUA 2026: Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Maxwell Sandberg discussing a study from the Intercontinental Collaboration of RCC assessing the impact of cytoreductive nephrectomy for RCC with tumor thrombus. Cytoreductive nephrectomy with tumor thrombectomy is a treatment option for patients with metastatic RCC with tumor thrombus. However, there is a paucity of research examining metastatic RCC with tumor thrombus patients at diagnosis, especially looking at the role of cytoreductive nephrectomy with tumor thrombectomy. As such, the purpose of this study, presented at the SESAUA 2026 annual meeting, was to report survival outcomes on metastatic RCC with tumor thrombus patients who underwent cytoreductive nephrectomy with tumor thrombectomy.
SES AUA 2026: Treatment of UTUC with UGN-101: Baseline Characteristics from the uTRACT Registry Study for UGN-101
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured an upper tract urothelial carcinoma session and presentation by Dr. Marc Bjurlin discussing baseline characteristics of patients from the uTRACT registry of UGN-101 treatment. Upper tract urothelial carcinoma affects 1-2 in 100,000 people in the United States annually. Endoscopically guided ablation is often used to treat low grade upper tract urothelial carcinoma; however, recurrence is common and long term surveillance is often associated with complications. UGN-101 is a reverse thermal hydrogel formulation of mitomycin for pyelocalyceal solution, FDA approved (April 2020), for chemoablative treatment of low grade upper tract urothelial carcinoma. In the phase 3 Olympus trial,1 UGN-101 was used as primary treatment of low grade upper tract urothelial carcinoma and resulted in clinically significant disease eradication and is associated with favorable long-term durability. The ongoing uTRACT registry is evaluating the real-world use of UGN-101. At the 2026 SESAUA annual meeting, Dr. Bjurlin presented baseline characteristics of the currently enrolled participants.
SES AUA 2026: Gemcitabine Intravesical System (TAR-200) Monotherapy in BCG-Unresponsive High-Risk NMIBC: Characterization of Recurrence, Progression, and Time to Radical Cystectomy
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Katie Murray discussing characterization of recurrence, progression, and time to cystectomy among patients undergoing gemcitabine intravesicle system monotherapy in BCG-unresponsive high-risk non-muscle invasive bladder cancer. Patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer have limited treatment options and a high risk of disease progression.
SES AUA 2026: Patient Reported Outcomes Before and After Treatment with UGN-102 in Adults with Recurrent Low-Grade Intermediate-Risk Non Muscle Invasive Bladder Cancer
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Trushar Patel discussing patient-reported outcomes before and after treatment with UGN-102 in adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Low-grade intermediate risk non-muscle invasive bladder cancer is typically managed with TURBT conducted under general anesthesia; disease recurrence is common.
SES AUA 2026: Physician Experiences with the Gemcitabine Intravesical System in High Risk NMIBC: A Qualitative Study of SunRISe Trial Investigators
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Timothy Lyon discussing a qualitative assessment of physician experiences using TAR-200 among investigators in the SunRISe trial. The gemcitabine intravesical system is a novel intravesical gemcitabine-releasing device under investigation for the treatment of patients with high-risk non-muscle invasive bladder cancer and muscle-invasive bladder cancer.
SES AUA 2026: First Results from CORE-008 Cohort A: A Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High Risk BCG-Naïve NMIBC
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Shreyas Joshi discussing the first results from CORE-008 cohort A assessing intravesical cretostimogene grenadenorepvec in patients with high risk BCG-naïve non muscle invasive bladder cancer. Standard of care treatment for high risk non muscle invasive bladder cancer includes TURBT followed by intravesical BCG. However, high recurrence rates and the persistent BCG shortage highlight the need for effective, well-tolerated, and readily available treatment options. While BCG demonstrates strong initial efficacy, durability remains a challenge: historical data report >50% of patients recur, and 20-40% are at risk of progression. Contemporary outcomes demonstrate improved durability with a 3-year event free survival/disease specific survival of >= 75%. However, 70% of patients experience side effects, leading to treatment discontinuation. Cretostimogene is an oncolytic immunotherapy designed to replicate in bladder cancer cells with Rb-E2F pathway alterations. In addition, cretostimogene expresses GM-CSF, adding to local and systemic cancer control:
SES AUA 2026: Durable 24-Month Outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-unresponsive Non Muscle Invasive Bladder Cancer with CIS
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Shreyas Joshi discussing durable 24-month outcomes from BOND-003 Cohort C assessing intravesical cretostimogene grenadenorepvec for high risk BCG-unresponsive non muscle invasive bladder cancer with CIS. A significant treatment gap exists for efficacious, well-tolerated bladder-sparing options for patients with high risk BCG-unresponsive non muscle invasive bladder cancer with CIS. Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to replicate in bladder cancer cells with Rb-E2F pathway alterations:
SES AUA 2026: Differences in Restaging TURBT Pathology Outcomes Based on Index TURBT Performed by an SUO Fellowship Trained or Non-SUO Trained Urologist
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Joon Kyung Kim discussing differences in restaging TURBT pathology outcomes based on index TURBT performed by an SUO fellowship trained or non-SUO trained urologist. TURBT has both diagnostic and therapeutic implications. For individuals diagnosed with T1 non muscle invasive bladder cancer, guidelines recommend restaging TURBT, given that up to 50% of individuals may have residual tumor and 20% may be understaged on repeat resection. Patients without residual T1 disease on restaging TURBT have decreased risk of recurrence and progression, and restaging TURBT can also reduce the risk of recurrence and progression compared to not performing a restaging TURBT at all.
SES AUA 2026: PSA and Alkaline Phosphatase Decline in the EORTC-1333 PEACE-3 Study Evaluating the Addition of Radium-223 in mCRPC Starting Enzalutamide
- Details
(UroToday.com) The 2026 SESAUA annual meeting featured a prostate cancer session and presentation by Dr. Murilo de Almeida Luz discussing PSA and alkaline phosphatase decline in the EORTC PEACE-3 study evaluating the addition of radium-223 in metastatic castration resistant prostate cancer (mCRPC) starting enzalutamide.